Table II.
Patient clinicopathological characteristics.
| Patients (N=320) | ||
|---|---|---|
|
|
||
| Characteristics | No. of patients | % |
| Median age (range), years | 50 (25–91) | |
| Clinical stage at diagnosis | ||
| I | 109 | 34.1 |
| II | 144 | 45.0 |
| III | 67 | 20.9 |
| Tumor stage (size cm) | ||
| T1 (≤2.0) | 157 | 49.1 |
| T2 (>2.0 to ≤5.0) | 131 | 40.9 |
| T3 (>5.0) | 26 | 8.1 |
| T4a | 6 | 1.9 |
| Nodal stage | ||
| N0 (node negative) | 178 | 55.6 |
| N1 (1–3 positive nodes) | 83 | 25.9 |
| N2 (4–9 positive nodes) | 36 | 11.3 |
| N3 (≥10 positive nodes) | 23 | 7.2 |
| Histological grade | ||
| Grade 1 | 16 | 5.0 |
| Grade 2 | 176 | 55.0 |
| Grade 3 | 128 | 40.0 |
| Subtypes of breast cancer | ||
| Luminal A-like | 71 | 22.2 |
| Luminal B-like | 186 | 58.1 |
| HER2 positive (non-luminal) | 27 | 8.4 |
| Triple negative (ductal) | 31 | 9.7 |
| Not known | 5 | 1.6 |
| ER status | ||
| Negative | 66 | 20.6 |
| Positive | 254 | 79.4 |
| PR status | ||
| Negative | 78 | 24.4 |
| Positive | 242 | 75.6 |
| HER2 status | ||
| Negative | 238 | 74.4 |
| Positive | 69 | 21.6 |
| Not known | 13 | 4.1 |
| Surgery | ||
| Mastectomy | 281 | 87.8 |
| Breast conservation | 39 | 12.2 |
| Chemotherapy | ||
| Neoadjuvant chemotherapy | 70 | 21.9 |
| Adjuvant chemotherapy | 165 | 51.6 |
| Not given | 85 | 26.6 |
| Targeted therapy | ||
| Herceptin | 12 | 3.8 |
| No herceptin | 308 | 96.3 |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
a
T4, tumor of any size with direct extension to the chest wall and/or to the skin.